Sansawi, Almoidz Y.
HRN: 22-95-57 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/25/2023
CEFOTAXIME 500MG (VIAL)
04/25/2023
05/01/2023
IVTT
285mg
Q6h
PCAP C, Bfc, T/C Sepsis
Waiting Final Action
Indication: Empiric Type of Infection: PneumoniaUnspecified Sepsis Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes